NGL Fine-Chem Peer Comparison

NSE: NGLFINE | BSE: 524774

₹2,832.40

₹-27.80 (-0.97%)

As on 06-Nov-2026IST

Market cap

₹1,736 Cr

Revenue (TTM)

₹536 Cr

P/E Ratio

30.3

P/B Ratio

Div. Yield

0.1 %

Edit

	NGL Fine-Chem	Sequent Scientific	Hester Biosciences	Emcure Pharmaceuticals	Piramal Pharma
Market cap (₹ Cr)	1,736	10,139	2,000	42,023	31,846
Revenue (₹ Cr)	536	3,149	326	10,234	9,779
Net Profit (₹ Cr)	57.20	213.79	129.56	1,092.67	-270.51
Net Margin (%)	10.35	6.70	38.70	10.67	-2.71
RoE (%)	18.17	10.42	14.64	21.65	-2.55
Price to Earnings	30.35	59.24	14.69	38.43	--
Price-To-Book	4.99	3.61	4.40	7.86	3.91

Income Statement (₹ Cr)

	NGL Fine-Chem	Sequent Scientific	Hester Biosciences	Emcure Pharmaceuticals	Piramal Pharma
Operating Revenue	536.16	3,148.72	325.74	10,234.10	9,778.62
Total Income	552.72	3,189.08	334.75	10,245.27	9,993.26
Total Expenditure	451.99	2,554.78	239.12	8,141.47	8,578.44
EBITDA	84.17	593.94	86.62	2,092.63	1,200.18
Depreciation	20.57	196.17	21.74	430.12	887.82
EBIT	63.60	397.77	64.88	1,662.51	312.36
Interest	4.23	57.29	12.20	151.49	347.94
Other Income	16.55	40.36	9.01	11.17	214.64
Exceptional Items	0.00	-42.96	88.29	-27.85	-216.88
Profit before Tax	75.92	337.88	149.97	1,494.35	-37.82
Provision for Tax	18.72	124.09	20.41	401.68	232.69
Profit after Tax	57.20	213.79	129.56	1,092.67	-270.51

	NGL Fine-Chem	Sequent Scientific	Hester Biosciences	Emcure Pharmaceuticals	Piramal Pharma
Shareholder's Funds	329.23	2,911.06	360.24	5,344.04	8,142.24
Minority Interest	0.00	-42.63	-0.74	0.82	0.55
Non-Current Liabilities	66.25	567.76	157.67	980.81	5,213.99
Current Liabilities	150.02	945.90	152.48	3,838.93	5,158.51
Total Liabilities	560.46	4,595.61	677.94	9,514.48	17,723.32

	NGL Fine-Chem	Sequent Scientific	Hester Biosciences	Emcure Pharmaceuticals	Piramal Pharma
Non-Current Assets	259.33	2,182.30	463.36	3,542.74	10,687.30
Current Assets	276.39	2,254.55	208.56	6,027.59	7,253.65
Total Assets	560.46	4,595.61	677.94	9,514.48	17,723.32
Total Debt*	122.50	435.81	188.26	1,204.08	5,495.48
Net Current Assets	126.37	1,308.65	56.08	2,188.66	2,095.14
Contingent Liabilities	0.80	26.69	--	258.92	95.72

	NGL Fine-Chem	Sequent Scientific	Hester Biosciences	Emcure Pharmaceuticals	Piramal Pharma
Cash From Operating Activities	43.32	322.91	64.14	943.55	1,652.60
Cash Flow from Investing Activities	-70.59	-84.12	-2.87	-1,193.06	-826.03
Cash from Financing Activities	29.55	-123.33	-48.79	343.43	-38.98
Net Cash Inflow / Outflow	2.27	115.46	12.48	93.92	787.59

	NGL Fine-Chem	Sequent Scientific	Hester Biosciences	Emcure Pharmaceuticals	Piramal Pharma
ROCE (%)	16.88	13.10	16.21	25.25	1.24
ROE (%)	18.17	10.42	14.64	21.65	-2.55
ROA (%)	11.69	6.86	19.46	11.17	-1.56
EBIT Margin (%)	11.86	12.63	19.92	16.24	3.19
Net Margin (%)	10.35	6.70	38.70	10.67	-2.71
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	NGL Fine-Chem	Sequent Scientific	Hester Biosciences	Emcure Pharmaceuticals	Piramal Pharma
Revenue Growth (%)	40.45	16.33	4.09	21.12	9.43
EBIT Growth (%)	214.27	127.71	31.42	32.84	-3.72
Net Profit Growth (%)	174.02	303.76	277.20	33.33	-199.34
EPS Growth (%)	174.02	3.66	35.90	38.63	-410.28
Book Value Growth (%)	16.57	20.14	14.63	11.36	0.33

	NGL Fine-Chem	Sequent Scientific	Hester Biosciences	Emcure Pharmaceuticals	Piramal Pharma
Price / Earnings	30.35	48.79	39.16	37.70	-153.14
Price / Book Value	4.99	3.61	4.40	7.86	3.91
Dividend Yield (%)	0.06	0.00	0.47	0.16	0.00
EV/EBITDA	21.55	17.35	25.19	20.59	29.98
Market Cap (₹ Cr)	1,279.54	8,003.17	1,074.13	30,257.56	18,108.89

	NGL Fine-Chem	Sequent Scientific	Hester Biosciences	Emcure Pharmaceuticals	Piramal Pharma
Debt to Equity	0.17	0.10	0.25	0.10	0.55
Short term debt to equity ratio	0.16	0.04	0.07	0.16	0.09
Current Ratio	1.84	2.38	1.37	1.57	1.41
Quick Ratio	1.37	1.53	0.89	0.92	0.77
Interest Coverage	18.95	6.90	13.29	10.86	0.89

	NGL Fine-Chem	Sequent Scientific	Hester Biosciences	Emcure Pharmaceuticals	Piramal Pharma
Debtors to sales (%)	24.41	33.20	29.27	26.69	23.05
Asset Turnover	1.10	1.01	0.49	1.05	0.56
Receivable days	77.86	98.80	92.43	88.68	78.20
Inventory Days	44.28	79.26	78.37	84.11	93.30
Payable days	88.92	126.90	120.46	176.65	226.14
Cash Conversion Cycle	33.22	51.16	50.33	-3.86	-54.64

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.